Corcept Therapeutics Incorporated (CORT) Stock
CORT Key Statistics
About Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
CEO: Joseph K. Belanoff. Company website
CORT — Frequently Asked Questions
What is the CORT stock price today?
Corcept Therapeutics Incorporated (CORT) trades at $110.29, down 3.98% on the day, as of Sep 20, 2026 14:57 UTC.
What is Corcept Therapeutics Incorporated's market cap?
Corcept Therapeutics Incorporated has a market capitalisation of $11.92B, calculated from the live CORT share price and shares outstanding.
What is the P/E ratio of CORT?
CORT trades at a trailing P/E of 262.60, from earnings per share of $0.42 over the last twelve months.
How much revenue does Corcept Therapeutics Incorporated make?
Corcept Therapeutics Incorporated generated revenue of $830.81M over the trailing twelve months, which puts the stock at 14.35 times sales.
What is the 52-week range for CORT?
CORT has traded between $28.66 and $126.38 over the past 52 weeks, and the last price is 12.7% below that high.
Is Corcept Therapeutics Incorporated profitable?
Yes. Corcept Therapeutics Incorporated keeps 6.61% of revenue as net income over the trailing twelve months.
What is the analyst price target for CORT?
Wall Street analysts rate CORT Buy, with an average price target of $125.33, 13.6% above the current price.
What sector is Corcept Therapeutics Incorporated in?
Corcept Therapeutics Incorporated is classified under the Healthcare sector and the Medical - Pharmaceuticals industry, and is domiciled in US.
Who is the CEO of Corcept Therapeutics Incorporated?
Joseph K. Belanoff is the chief executive of Corcept Therapeutics Incorporated, which employs 730 people.
Where can I track CORT in real time?
QFI Terminal shows CORT with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See CORT live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open CORT in Terminal See plans